CLDN6 and ovarian carcinoma: On the basis of promising clinical activities in the NCT05103683 clinical trial, a registry phase II clinical trial of ixotatug vedotin for the treatment of CLDN6-positive platinum-resistant epithelial ovarian cancer is ongoing (CATALINA-2 study, NCT06690775).